2seventy bio (TSVT) Reports Preliminary Full-Year U.S. Abecma Sales

2seventy bio, Inc. (Nasdaq: TSVT) today provided full-year Abecma® (idecabtagene vicleucel; ide-cel) sales results for 2024, in partnership with Bristol Myers Squibb (BMS).

“We are pleased to see Abecma expansion in the third line setting and recorded U.S. revenue of $242 million in 2024, within our previously issued guidance of $240 to $250 million. Fourth quarter revenue was impacted by higher deferrals of infusions into 2025. We expect the use of CAR-T in multiple myeloma will continue to grow, and while competition remains high, we believe Abecma will continue to make a meaningful difference in the lives of patients,” said Chip Baird, chief executive officer, 2seventy bio. “Equally important is that our Abecma-focused strategy, which led to the monetization of our R&D assets and streamlining of our operations, has put us on track to achieve quarterly breakeven later this year based on our current expectations. We remain committed to maximizing value for stakeholders and look forward to sharing more detail during our earnings call next month.”

Further details on fourth quarter and full year 2024 results will be provided on the Company’s earnings call and within its Form 10-K, which is expected to be filed with the SEC by no later than March 17, 2025.

2seventy bio and BMS share equally in all profits and losses related to development, manufacturing, and commercialization of Abecma in the U.S.

*Fourth quarter and full-year 2024 financial results are preliminary, unaudited, and provided as an approximation in advance of 2seventy bio’s announcement of complete financial results in March 2025. This information is based on currently available information. Final results may therefore vary from these estimates. These preliminary estimates have not been audited by 2seventy bio’s independent registered public accounting firm.

You May Also Be Interested In

• Faraday Future signs robotics distributor deal, plans partner event
• BofA maintains underperform ratings on six BDC stocks
• Silexion Therapeutics faces Nasdaq delisting over equity shortfall